Zytiga cost too high, says NICE
Zytiga (abiraterone) is not recommended, in combination with steroids prednisone or prednisolone, as a second-line treatment for metastatic, castration-resistant prostate cancer in patients who have failed on Sanofi's Taxotere.
NICE draft "no" for ZytigaPharma Times
Charities condemn 'no' decision on prostate drugOnMedica
NICE turns down 'expensive' prostate cancer drugNetdoctor -The Pharma Letter (subscription)
all 267 news articles »